First Time Loading...

Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 27.21 USD -0.4% Market Closed
Updated: May 6, 2024

Pacira Biosciences Inc
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Pacira Biosciences Inc
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Pacira Biosciences Inc
NASDAQ:PCRX
Operating Income
$87.3m
CAGR 3-Years
13%
CAGR 5-Years
38%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.3B
CAGR 3-Years
4%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$10.5B
CAGR 3-Years
14%
CAGR 5-Years
6%
CAGR 10-Years
12%
Pfizer Inc
NYSE:PFE
Operating Income
$10.6B
CAGR 3-Years
-6%
CAGR 5-Years
11%
CAGR 10-Years
-5%
Merck & Co Inc
NYSE:MRK
Operating Income
$6.6B
CAGR 3-Years
-10%
CAGR 5-Years
-11%
CAGR 10-Years
-2%
Eli Lilly and Co
NYSE:LLY
Operating Income
$11.3B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
9%

See Also

What is Pacira Biosciences Inc's Operating Income?
Operating Income
87.3m USD

Based on the financial report for Dec 31, 2023, Pacira Biosciences Inc's Operating Income amounts to 87.3m USD.

What is Pacira Biosciences Inc's Operating Income growth rate?
Operating Income CAGR 5Y
38%

Over the last year, the Operating Income growth was 23%. The average annual Operating Income growth rates for Pacira Biosciences Inc have been 13% over the past three years , 38% over the past five years .